Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research
Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event.
With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide.
In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will support Synteract by sharing ideas, best practices in study designs, protocol review intended for pediatric treatment, and patient facing documents review to help increase recruitment and enhance the quality and benefit of pediatric clinical trials and pediatric research. Both organizations will capitalize on opportunities for innovation in leveraging their respective expertise to enable children and their families to take ownership of their health, provide meaningful input into regulations, and improve design and conduct of pediatric studies worldwide.
“At iCAN, we are dedicated to advancing the health and well-being of children around the world. An important part of that is collaborating with established partners, such as Synteract in the pediatric clinical trials space,” said Leanne West, president of iCAN. “We look forward to working together to leverage Synteract’s extensive knowledge, industry experience, and drug development acumen to further advance pediatric clinical research and increase availability of medicines to help children.”
Synteract has been at the forefront of working with sponsors in pediatric clinical trials for three decades, with 100 pediatric studies performed worldwide across multiple therapeutic indications. It recently announced pediatrics drug development as one of its focused therapeutic centers of development.
Dr. Martine Dehlinger-Kremer heads up the pediatric center of development at Synteract, as vice president, Pediatric Development. She is also President of EUCROF, the European CRO Federation; Chair of the Pediatric Working Group of EUCROF since 2008, and Chair of the European Forum for GCP Children Medicines Working Party. She was appointed Observer Member of the Coordinating Group of Enpr-EMA, the European Network of Pediatric Research at the European Medicines Agency (EMA), in April 2018, and has been a member of Working Parties of Enpr-EMA for several years.
“At Synteract we remain committed to advancing standards and assisting sponsors to address growing needs for pediatric clinical research,” said Dr. Dehlinger-Kremer. “By partnering with iCAN, we gain access to its wide network of children and families spanning socioeconomic, cultural, and geographic backgrounds, which will be beneficial for the development of medicines for children. Our partnership with iCAN will be valuable in developing better, more appropriate protocols, study designs, patient facing documents and setting strategy for recruitment. It will also help us to further innovation in systems and treatments. It is another important step to show our commitment to this important population.”
iCAN is supported by the Foundation for Children, the 501 (c) 3 nonprofit arm of the Connecticut Chapter of the American Academy of Pediatrics (CT-AAP).
With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in pediatric, oncology and neuro degenerative indications, as well as rare and orphan and immunotherapy studies.
Hilary McCarthy, 508-829-2543
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma20.9.2018 20:21 | Tiedote
Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.1,2 The EC decision is applicable to all 28 European Union (EU) member states plus Liechtenstein, Iceland and Norway. "We are extremely pleased that European patients with advanced BRAF-mutant melanoma will now have the combination of BRAFTOVI and MEKTOVI as a new treatment option”, said Frédéric Duchesne, President & CEO of the Pierre Fabre Pharmaceuticals Division. “All of us at Pierre Fabre are driven to make a real difference for patients. Bringing more than 30 years of oncology experience and our heritage in dermatology to our partnership with Array BioPharma, we have been able to harness our expertise in order to help men and women living with this devastating disease. Today’s
Clothesource Report Shows Retail Sales Aren’t Falling or Moving Online: Management’s Let Itself Get Misguided20.9.2018 20:19 | Tiedote
According to a new Clothesource report, “The Emperors’ Clothes” retail sales aren’t falling, and they’re not leaving physical stores. Both the UK’s Office of National Statistics and the US Bureau of the Census report higher retail sales than ever – with sales in physical stores still growing every year. Retailers just need to rely on their own customer understanding, recapture their self-confidence, and rediscover their traditional frugality. Among recent front-page stories have been Sears in the US hinting it’s about to go under and profits at Britain’s John Lewis falling 99%. But the well run clothing retailers are prospering. Primark goes from strength to strength: the biggest clothing specialists on either side of the Atlantic (Inditex and TJX) have just upped their sales and profit forecasts. So it’s not about consumer purchasing: The main problem lies with management, says Clothesource CEO Mike Flanagan in a new report “The Emperors’ Clothes”. They’ve lost touch with their custom
BCW Names Latin America Market Leaders20.9.2018 19:23 | Tiedote
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced the appointment of market leaders in Latin America who will be responsible for business growth, client satisfaction and talent development. All market leaders report to Francisco Carvalho, President, Latin America, BCW. “BCW has a dominant presence in Latin America, thanks to Burson-Marsteller’s 40-year-history and expansive footprint across the region and Cohn & Wolfe’s strength in Brazil and Mexico,” said Carvalho. “This team has unmatched market knowledge, strong client relationships and deep commitment to talent, all of which is critical for our continued success in the region. Those strengths, together with our industry-leading expertise in delivering digitally driven integrated communications programs, make BCW a powerful partner for our clients.” All of BCW’s Latin America market leaders have been drawn from the legacy Burson-Marsteller organization and had been leading their respective markets, e
NavVis Achieves Breakthough 6D SLAM Indoor LiDAR Mapping With Velodyne’s 3D LiDAR Sensor20.9.2018 17:43 | Tiedote
On April 18th, 2018, NavVis released their M6, a fully-integrated, cart-based system designed for large-scale indoor mapping. The M6 utilizes VLP-16 sensors by Velodyne LiDAR, Inc., which allows it to produce a 3D map of the surrounding environment. Six cameras capture 360° immersive imagery and photorealistic point-clouds, resulting in high-resolution mapped images. NavVis developed this product in response to their customers’ request for a more versatile and sophisticated system which could be used effectively with uneven terrain. In addition to AEC professionals, construction companies and manufacturers can also draw benefits from the higher data quality provided by this enhanced innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005560/en/ NavVis M6 is a fully-integrated, cart-based system designed for large-scale indoor mapping. (Photo: Business Wire) The M6 was developed by NavVis after customers requeste
Steve Bannon’s New Documentary Film Trump @War Launches Free Online Access20.9.2018 17:34 | Tiedote
Trump @War in conjunction with its online distribution partner, The Western Journal, is pleased to announce that the full length HD feature film Trump @War is free and available to viewers worldwide at Trumpmovienow.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005553/en/ Watch free full-length feature film: trumpmovienow.com (Photo: Business Wire) “The Western Journal does great work and we are happy they are partnering with us,” stated Stephen K. Bannon. “It’s a film that every American, regardless of political belief, should watch. It’s a historic time for our country, and no one should be sitting on the sidelines during the upcoming elections.” Directed by Bannon and produced by Dan Fleuette, Trump @War is a retelling of the most significant election campaign in modern U.S. history and a look forward to the high-stakes midterm election in November 2018, which will cement President Trump’s legacy. “Steve Banno
GTIS Partners Grabs Top Spots in Prestigious GRESB Sustainability Ranking20.9.2018 17:24 | Tiedote
GTIS Partners LP (“GTIS”), a real assets investment firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris and Munich, today announced that the GTIS Brazil Real Estate Fund (“GTIS Brazil Real Estate Fund I”) has been recognized as 2018’s most sustainable private equity real estate investment fund in South America by the Global Real Estate Sustainability Benchmark (GRESB). This is the fourth year running the fund has clinched the top ranking. GTIS Brazil Real Estate Funds II and III took second- and third-place honors, respectively, matching the funds’ 2017 survey rankings. “Our across-the-board top-place rankings are a testament to the day-in, day-out efforts of the entire GTIS Brazil team, who’ve incorporated environmental, social and governance principles into their investment and management practices,” said Josh Pristaw, Senior Managing Director, Head of Capital Markets and Co-head of Brazil at GTIS Partners. “What we’re most proud
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme